NeuroinflammationApril 2026
2026 Review: Nanobody Therapeutics in Alzheimer's — From Molecular Mechanisms to Translational Approaches
A comprehensive review published in Antibodies (2026) analyzes the potential of VHH nanobodies in Alzheimer's: neutralization of toxic Aβ oligomers, inhibition of tau aggregation, and modulation of neuroinflammation. Their small size, stability, and specificity position them as superior to conventional antibodies and small molecules for CNS targets.
JFInnova Perspective
This review confirms the modality advantages JFInnova chose from the start. JFIN-0001 combines the inherent VHH properties (12.6 kDa, high stability, BBB penetration) with a fully in silico design — enabling rapid iteration and optimization without the limitations of wet-lab screening.
References
Nanobody Alzheimer VHH BBB therapeutic